Issue Date: March 13, 2017
Otsuka to acquire Neurovance
Otsuka Pharmaceutical will pay $100 million up front and up to $150 million in potential milestone payments to acquire Cambridge, Mass.-based Neurovance, a six-year-old company focused on attention-deficit/hyperactivity disorder. Its lead ADHD candidate is centanafadine, which has completed Phase II clinical trials. According to Neurovance, centanafadine is one of a new generation of triple reuptake inhibitors that modulate the activity of norepinephrine, dopamine, and serotonin. The acquisition will extend Otsuka’s efforts in the area of . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society